in the present study , 6 patients were treated who developed graft-versus-host disease ( gvhd ) following allogeneic bone marrow transplantation ( bmt ) with thalidomide and in a dose range of 200-600 mg daily .
C0018133
graft-versus-host disease
C0039736
thalidomide